Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
STRO Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 25, 2026
Report Source: 2026 1st Quarter Report
Sutro Biopharma Inc. Stock Analysis STRO
United States Health Care Small Cap Report: Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 137 full-time employees. The company went IPO on 2018-09-27. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Read More Sutro Biopharma Inc (STRO) Chart
Key Statistics of Sutro Biopharma Inc (STRO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$30.67Volume
226.91KP/E Ratio (TTM)
-52 Week Range
Market Cap
507.39MAvg. Volume
332.04KDividend Yield
-Financial Metrics & Statements of Sutro Biopharma Inc (STRO)
FAQ's for Sutro Biopharma Inc (STRO)
- According to Musaffa’s Shariah screening methodology, Sutro Biopharma Inc (STRO) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sutro Biopharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Sutro Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Sutro Biopharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Sutro Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Sutro Biopharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.